Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Ipsen will acquire biotech firm Epizyme for $247 million

by Michael McCoy
June 30, 2022 | A version of this story appeared in Volume 100, Issue 24

The structure of tazemetostat.

The French drug company Ipsen has agreed to acquire Epizyme for $247 million in cash plus milestone payments based on sales performance for Tazverik. Epizyme won US Food and Drug Administration approval for Tazverik (tazemetostat) in 2020 as a treatment for follicular lymphoma. Ipsen’s deal also includes EZM0414, a small molecule Epizyme is developing for multiple myeloma and lymphoma.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.